Boucher & Muir Pty Ltd (BNM) was incorporated in 1957 by Sydney Frish and Otto Ekstein. Through its humble beginnings, BNM has developed into a main stream pharmaceutical company serving the domestic and internal markets including NZ and Pacific Island countries. Using its long trading history and pharmaceutical market knowledge, combined with its young and highly energetic employees, BNM has carefully carved its niche in the crowded pharmaceuticals market.
In 2015 BNM was acquired by AMCo, after ten years of BNM being one of AMCo's main distributors for medicines in the region. Later that same year, BNM and AMCo came under the ownership of the Canadian Concordia Healthcare Corp (TSX, NASDAQ) through its acquisition of AMCo. BNM continues to espouse strong family values in its daily operations. These values form the backbone of the company's mission to protect the health of families through the provision of quality medicines and medical products.
Since 1964, they have maintained their position as one of the leading medical suppliers to governments of the independent nations in this region, including:
Actively involved in the supply for aid funded projects
Because of their long experience in dealing with the South Pacific Island Health sector, they are often contacted by Aid Agencies requesting information on health issues.
They are also actively involved in the supplies for a number of Aid funded projects initiated by the following agencies:
Their reputation for quality is their most important asset
In the South Pacific Islands, they recognise that their reputation for quality and reliability are their most important assets.
All pharmaceuticals supplied by their company are manufactured under GMP (Good Manufacturing Practice) legislation and in accordance with the appropriate WHO standards and BP/USP Pharmacopoeia.
All of their international pharmaceutical manufacturers must also be able to demonstrate ongoing product compliance to the appropriate standards, borth internationally and within their own countries.
